Trevena (TRVN)
(Delayed Data from NSDQ)
$0.20 USD
-0.03 (-13.17%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.20 0.00 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.20 USD
-0.03 (-13.17%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.20 0.00 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Zacks News
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
by Zacks Equity Research
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TRVN) Outperforming Other Medical Stocks This Year?
PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
by Zacks Equity Research
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Will Trevena Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Trevena.
Implied Volatility Surging for Trevena (TRVN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
4 Healthcare Stocks Thriving on Venture Capital Funding
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Implied Volatility Surging for Trevena (TRVN) Stock Options
by Zacks Equity Research
Trevena (TRVN) needs investors to pay close attention to the stock based on moves in the options market lately.
Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%
by Zacks Equity Research
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares nearly 12% on the day amid huge volumes.
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.
What Makes Trevena (TRVN) a Strong Sell?
by Zacks Equity Research
Trevena (TRVN) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.